Evidence map›Paper›PMID 41468463›Full record

ArticlePloS one2025

The practice of drug emergency supply in China during the COVID-19 pandemic: A policy mix perspective.

Zhang Jie-Ying, Li Jun, Wang Xue-Ya, Fan Rui-Xue, Zhao Feng, Tang Yi, Zhang Jun-Lin, Mao Ning-Ying

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhang Jie-YingInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Li JunInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Wang Xue-YaInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Fan Rui-XueInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Zhao FengInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Tang YiInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Zhang Jun-LinInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.
Mao Ning-YingInternational Pharmaceutical Business School of China Pharmaceutical University, Nanjing, Jiangsu, China.ORCID https://orcid.org/0009-0002-2105-3921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPublic health emergencies such as COVID-19 severely disrupt drug supply chains, creating sudden surges in demand, labor shortages, and regulatory challenges. Existing studies often focus on single supply chain stages, with limited systematic analysis of policy responses across the entire cycle.

objectivesThis study aims to systematically analyze China's emergency drug supply policies by examining issuing agencies, developmental stages, policy tools, and supply chain links, to identify patterns, complementarities, and existing gaps.

methodsA total of 559 policy texts (110 national, 449 provincial) issued between December 2019 and February 2023 were collected. Content analysis and coding were conducted based on a four-dimensional framework. Social network analysis was applied to joint policy issuances to assess institutional collaboration and centrality.

resultsNational policies emphasized macro-level planning and dynamic adjustment: motivation and symbolic tools dominated in the burst stage, commands and regulations in the remission stage, and symbolic tools in later stages. Provincial policies relied more on rigid enforcement through commands and regulations, gradually shifting toward capacity-building in distribution and use. Finance, healthcare security, and regulatory agencies emerged as network hubs, while the distribution stage received the most policy support. Raw material supply was largely overlooked.

conclusionsNational and provincial policies demonstrated complementary functions-national policies providing strategic direction and provincial policies ensuring operational enforcement. However, imbalances in policy tool use, weak shortage monitoring, and insufficient human resource policies remain. Future research should incorporate municipal-level measures, field-based evaluations, and international comparisons to optimize China's emergency drug supply governance.

Indexed as

COVID-19Health PolicyChinaEmergenciesHumansPandemicsPharmaceutical PreparationsSARS-CoV-2Pharmaceutical Preparations

Identifiers

PMID41468463
PMCPMC12753071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.